2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Lung Diseases
2
Lung Non-Squamous Non-Small Cell Carcinoma
1
Lung Neoplasms
1
Carcinoma
1
Interventions
Carboplatin
345
Cisplatin
240
Paclitaxel
208
Radiotherapy
206
Pemetrexed
190
Docetaxel
170
Gemcitabine
158
pembrolizumab
146
Erlotinib Hydrochloride
111
Magnetic Resonance Spectroscopy
101
Etoposide
98
Bevacizumab
96
Specimen Handling
84
Nivolumab
77
durvalumab
73
Radiosurgery
73
Blood Specimen Collection
65
Drug Therapy
61
osimertinib
56
Vinorelbine
54
Gefitinib
50
Surveys and Questionnaires
48
atezolizumab
44
Biopsy
43
Irinotecan
42
Radiation
41
Topotecan
39
Standard of Care
38
Cyclophosphamide
38
Surgical Procedures, Operative
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
zipalertinib
×
Clear all
NCT07128199
2026-05-05
REZILIENT4
Taiho Oncology, Inc.
Phase 3
Active not recruiting
360 enrolled